Related Experiment Videos
beta-Glucuronidase levels in patients with fibrocystic breast disease
Abstract:
Certain enzymes in tissues and body fluids may, through reversal of the detoxification process, influence the composition and availability of steroid hormones, toxins, and carcinogens. The ubiquitous enzyme beta-glucuronidase, which hydrolyzes glucuronide conjugates, thereby reversing one of the main detoxification and excretion pathways, was found to vary in concentration in different cysts over a 300-fold range. The distribution was a continuum, devoid of discrete sub-populations. Evidence obtained on selected cyst fluids of high and low beta-glucuronidase activities indicated that the level of the enzyme significantly influenced the ratio of unconjugated: glucuronidated estradiol. The patients with fibrocystic breast disease fell into 2 distinct subpopulations on the basis of their serum beta-glucuronidase activity. In one group the activity was near normal, while in the second group the average serum beta-glucuronidase activity was 3-fold higher than in the women who did not have benign breast disease.
Insights
Beta-glucuronidase enzyme activity in breast cysts varied significantly. Higher serum beta-glucuronidase levels were observed in women with fibrocystic breast disease, impacting steroid hormone balance.
Area of Science:
- Biochemistry
- Endocrinology
- Oncology
Background:
- Enzymes in body fluids can alter steroid hormone, toxin, and carcinogen levels by reversing detoxification.
- Beta-glucuronidase (GUS) is a key enzyme in reversing glucuronide conjugation, a major detoxification pathway.
Purpose of the Study:
- To investigate the role of beta-glucuronidase (GUS) in steroid hormone metabolism within breast cysts.
- To determine if GUS activity differentiates patient populations with benign breast disease.
Main Methods:
- Quantified beta-glucuronidase (GUS) activity in various cyst fluids.
- Analyzed the ratio of unconjugated to glucuronidated estradiol in relation to GUS levels.
- Compared serum GUS activity in patients with fibrocystic breast disease (FBD) versus controls.
Main Results:
- Beta-glucuronidase (GUS) concentrations varied up to 300-fold across different cysts.
- Elevated GUS activity in cyst fluid correlated with increased unconjugated: glucuronidated estradiol ratios.
- Patients with fibrocystic breast disease (FBD) showed two distinct serum GUS activity groups: near-normal and 3-fold higher than controls.
Conclusions:
- Beta-glucuronidase (GUS) activity significantly influences local steroid hormone bioavailability in breast cysts.
- Serum beta-glucuronidase (GUS) activity may serve as a biomarker for fibrocystic breast disease (FBD) sub-populations.